Variable Landscape of PD-L1 Expression in Breast Carcinoma as Detected by the DAKO 22C3 Immunohistochemistry Assay

BACKGROUND: In 2020, pembrolizumab was approved as a therapy for triple-negative breast cancer (TNBC) with the companion diagnostic DAKO 22C3 programmed death ligand-1 (PD-L1) immunohistochemistry assay. The study aimed to determine the landscape of PD-L1 expression as detected by the DAKO 22C3 PD-L...

Descripción completa

Detalles Bibliográficos
Autores principales: Danziger, Natalie, Sokol, Ethan S, Graf, Ryon P, Hiemenz, Matthew C, Maule, Jake, Parimi, Vamsi, Palmieri, Carlo, Pusztai, Lajos, Ross, Jeffrey S, Huang, Richard S P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Cancer Diagnostics and Molecular Pathology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10078903/
https://www.ncbi.nlm.nih.gov/pubmed/36866462
http://dx.doi.org/10.1093/oncolo/oyad025

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10078903/
https://www.ncbi.nlm.nih.gov/pubmed/36866462
http://dx.doi.org/10.1093/oncolo/oyad025

Ejemplares similares